Global Peptide Therapeutics Market – Industry Trends and Forecast to 2030

Global Peptide Therapeutics Market, By Type (Branded Peptide, Generic Peptide), Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Others), Route of Administration (Oral Administration, Parenteral Administration, Pulmonary Administration, Mucosal Administration, Injection Administration) - Industry Trends and Forecast to 2030.

Peptide Therapeutics Market Analysis and Size

The growing incidences of cancer and metabolic disorders, such as osteoporosis, obesity, and diabetes are some of the key factors anticipated to propel the growth of the peptide therapeutics market in the forecast period. The need for effective and economical prices drugs is very large because of the increasing base of affected paediatric population and the incidences of target diseases in the economical countries. The market is estimated to show advantageous amount of growth in the peptide therapeutics market because of the actions taken by many companies for inspecting the development of new drug candidates. The CMOs which offer end-to-end solution to the biotech pharmaceutical companies are increasing because of the shift in the focus of pharma companies to search better opportunities in the peptide therapeutics market.

Data Bridge Market Research analyses that the Peptide therapeutics market which was USD 44,699.15 million in 2023, would rocket up to USD 68,553.89 million by 2030, and is expected to undergo a CAGR of 6.3% during the forecast period. This indicates that the market value. "Multivitamin" dominates the product type segment of the Peptide therapeutics market due to increasing awareness about the Peptide therapeutics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Peptide Therapeutics Market Scope and Segmentation

Market Definition

Peptides are the connection of two or more amino acid monomers joined by amide bonds. Peptide is distinguished from proteins on the basis of the size. Molecules with not more than 50 amino acids are treated as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and aid in the treatment of diseases by aiding on the cell membrane.

Peptide Therapeutics Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

Peptide therapeutics have gained significant attention in the treatment of chronic diseases such as cancer, diabetes, cardiovascular disorders, and metabolic disorders. The rising incidence of these diseases worldwide is driving the demand for peptide-based drugs.

• Increasing Demand for Personalized Medicine

Peptide therapeutics offer the potential for personalized medicine due to their high specificity and low toxicity. As the demand for personalized treatment approaches grows, peptides are being explored as a viable option for targeted therapies, driving the market growth.

• Growing R&D Investments

Pharmaceutical and biotechnology companies, as well as academic research institutions, are increasingly investing in research and development activities related to peptide therapeutics. The availability of funding and a strong focus on drug discovery and development are propelling the growth of the market.  

Opportunity

• Advancements in Peptide Synthesis Technologies

Recent advancements in peptide synthesis technologies have made it easier and more cost-effective to produce complex peptides with improved stability and bioavailability. These technological developments have expanded the possibilities for peptide-based drug development, leading to a wider range of therapeutic options.

Restraints/Challenges

• Regulatory Challenges

Obtaining regulatory approvals for new peptide therapeutics involves rigorous testing and evaluation processes. These regulatory hurdles can significantly delay the launch of new drugs, increasing development costs and limiting the market entry of innovative treatments. Adhering to these regulations and obtaining necessary approvals can be time-consuming and costly, hindering market growth.

This peptide therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Peptide therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In June 2023, IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD outside the USA and Canada, to continue their collaboration in the peptide therapeutics area.

Global Peptide therapeutics Market Scope

The peptide therapeutics market is segmented on the basis of type, application, and route of administration. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Type

• Branded Peptide
• Generic Peptide

Application

• Cancer
• Velcade (Bortezomib)
• Zoladex (Goserelin)
• Lupron/ Enantone/ Eligard (Leuprorelin)
• Cardiovascular Disease
• Integrilin (Eptifibatide)
• Angiomax (Bivalirudin)
• Metabolic Disease
• Byetta (Exenatide)
• Victoza (Liraglutide)
• Respiratory Disease
• Gastro-Intestinal Infection (GIT)
• 1 Linzess (Linaclotide)
• Gattex (Teduglutide)
• Infectious Disease
• Victrelis (Boceprevir)
• Incivek (Telaprevir)
• Hematological Disorders
• Kalbitor (Ecallantide)
• Firazyr (Icatibant)
• Others

Route of Administration

• Oral Administration
• Parenteral Administration
• Pulmonary Administration
• Mucosal Administration
• Injection Administration

Peptide Therapeutics Market Regional Analysis/Insights

The peptide therapeutics market is analysed and market size insights and trends are provided by country, type, application, and route of administration, as referenced above.

The countries covered in the peptide therapeutics market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa.

 The North America is expected to dominate the global peptide therapeutics market due to increasing prevalence of cancer in that region.

Asia-Pacific is the fastest growing region due to increase rising awareness about peptide therapeutics.

The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The peptide therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for peptide therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2010-2020.

Competitive Landscape and Peptide Therapeutics Market Share Analysis

The peptide therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the peptide therapeutics market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd, (Israel)
• Ipsen Pharma (France)
• AstraZeneca (UK)
• Lonza (Switzerland)
• Merck Sharp & Dohme Corp. (U.S.)
• Novo Nordisk A/S (Denmark)
• PolyPeptide Group (Switzerland)
• CordenPharma International (Germany)